Current stock page

Financial Data

ORKA Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

ORKAOruka Therapeutics, Inc.

Healthcare / Biotechnology

Leader

Sector Leader

BullishEdge 10/10
$105.35+$0.36 (+0.34%)

Latest quote

  • Momentum
    81
  • Value
    —
  • Quality
    83
  • Risk resilience
    53
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$0$0$0$0$0$0$0$0
Gross Profit-$49K-$43K-$43K-$28K$0$0$0$0
Operating Income-$62.14M-$50.11M-$36.43M-$34.43M-$34.11M-$28.43M-$25.09M-$38.33M
Net Income-$49.97M-$41.21M-$31.82M-$29.58M-$30.28M-$24.57M-$21M-$33.39M
EPS-$0.63-$0.66-$0.58-$0.54-$0.69-$0.58-$0.5-$1.54
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$44.33M-$33.15M-$23.58M-$22.59M-$21.6M-$23.15M-$20.87M-$18.82M
Capital Expenditure-$83K$0-$73K-$63K-$99K-$34K-$13K-$18K
Free Cash Flow-$44.41M-$33.15M-$23.65M-$22.66M-$21.7M-$23.18M-$20.88M-$18.84M
Net Cash Provided By Operating Activities-$44.33M-$33.15M-$23.58M-$22.59M-$21.6M-$23.15M-$20.87M-$18.82M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$1.23B$1.14B$504.48M$488.62M$509.25M$357.42M$377.11M$396.02M
Total Debt$2.93M$2.55M$1.81M$1.93M$1.91M$2.33M$947K$968K
Cash And Cash Equivalents$191.52M$268.47M$49.52M$46.94M$91.25M$65.4M$83.57M$61.58M
Total Liabilities$33.88M$24.85M$17.76M$16.69M$22.46M$13.78M$12.39M$13.8M
Total Stockholders Equity$1.2B$1.11B$486.72M$471.93M$486.79M$343.64M$364.73M$382.22M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio6.255.41——————
P/S ratio————————
Debt To Equity000000.0100
Free Cash Flow Yield-1.65%-1.68%——————
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio6.255.41——————
P/S ratio————————
Return On Equity-12.74%-11.92%-23.89%-22.34%-22.44%-31.31%-28.86%-22.57%
Debt To Equity000000.0100

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-43.71x
Pb6.3x
EPS Growth Yoy8.70%
Gross Margin0.00%
Operating Margin0.00%
ROE-18.66%
ROIC-15.26%
Debt To Equity0
FCF Yield-1.73%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$105.35
Volume679,679
RSI (14)64.42
MACD5.67
MACD signal4.41
MACD histogram1.25
ADX (14)35.23
SMA (50)$89.68
SMA (200)$72.65
ATR (14)$5.66
Historical volatility (annualized)64.29%
Volume (20-day average)998,113

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score53/100
Beta1.4
Annual volatility69.09%
Max Drawdown-36.39%
Sharpe Ratio2.29
VaR (95%, 1-day)-5.26%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

ORKA Financial Data FAQ

What is Oruka Therapeutics, Inc.'s revenue?

Oruka Therapeutics, Inc.'s revenue is one of the core financial data points for ORKA. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Oruka Therapeutics, Inc.'s revenue growing?

Revenue growth shows whether Oruka Therapeutics, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is ORKA's EPS?

ORKA's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Oruka Therapeutics, Inc.'s net income?

Oruka Therapeutics, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Oruka Therapeutics, Inc. generate?

Free cash flow shows how much cash Oruka Therapeutics, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Oruka Therapeutics, Inc. have?

Cash and debt help frame ORKA's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.